|
Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference WHAT: Onyx Phamaceuticals, Inc. (Nasdaq: ONXX - news) to present on progress with its novel lead product, CI-1042 (ONYX-015), for treatment of head and neck cancer, and its other products in clinical development at the Biotechnology Industry Organization (BIO) CEO & Investor Conference 2001 in New York, NY. The presentation will be web cast for investors from the following site: http://www.informedinvestors.com/iif_forums/event.cfm?forumI… . The Onyx presentation will be available "real-time" over the Internet; click on the above link and scroll to "click to listen" opposite Onyx (listed under company names); replay will be available for up to 90 days. WHO: Hollings C. Renton, Chairman and Chief Executive Officer of Onyx, Member of BIO`s Board of Directors WHEN: Wednesday, February 21, 2001 at 9:30 a.m. EST WHERE: BIO CEO & Investor Conference 2001 The Waldorf-Astoria Basildon Room 301 Park Avenue New York, NY 10022 Contact: Helen Kim, 510-262-8737, ir@onyx-pharm.com Betsy Rosenberg, 415-221-6854, bprcomm@yahoo.com About Onyx Onyx Pharmaceuticals is engaged in the discovery and development of novel targeted, highly selective cancer therapies. Based on its proprietary virus technologies, the company is developing its lead product, CI-1042 (ONYX-015), a tumor-selective, modified adenovirus (similar to the common cold virus) that has been genetically engineered to replicate in and lyse (burst) cancer cells that have abnormal p53 pathway function, while sparing normal cells that have normal p53 pathway function. p53 is the most common genetically altered protein in human cancer. CI-1042 (ONYX-015) is being jointly developed by Onyx and Pfizer Inc. (NYSE: PFE - news). CI-1042 (ONYX-015) is currently in a Phase III clinical trial for head and neck cancer and in Phase I and II clinical trials for a number of different additional cancer indications. For more information about CI-1042 (ONYX-015) and Onyx`s pipeline and activities, visit Onyx`s Web site at www.onyx-pharm.com. SOURCE: Onyx Pharmaceuticals, Inc. |
|
| aus der Diskussion: | onyx pharmaceut. im juhu musterdepot! |
| Autor (Datum des Eintrages): | panik (18.02.01 15:49:50) |
| Beitrag: | 13 von 229 (ID:2931988) |
| Alle Angaben ohne Gewähr © wallstreetONLINE | |